ZYTIGA 250 mg TABLETS
How to use ZYTIGA 250 mg TABLETS
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
ZYTIGA 250 mg tablets
abiraterone acetate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What ZYTIGA is and what it is used for
- What you need to know before you take ZYTIGA
- How to take ZYTIGA
- Possible side effects
- Storage of ZYTIGA
- Contents of the pack and other information
1. What ZYTIGA is and what it is used for
ZYTIGA contains the active substance abiraterone acetate. It is used for the treatment of prostate cancer in adult men that has spread to other parts of the body. ZYTIGA stops your body from making testosterone; this can slow down the growth of your prostate cancer.
When ZYTIGA is prescribed in the early stages of the disease and you are still responding to hormone treatment, it is used together with treatment to lower testosterone levels (androgen deprivation treatment).
When you take this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone to reduce the risk of high blood pressure, fluid retention, or low potassium levels in your blood.
2. What you need to know before you take ZYTIGA
Do not take ZYTIGA
- if you are allergic to abiraterone acetate or any of the other ingredients of this medicine (listed in section 6).
- if you are a woman, especially if you are pregnant. ZYTIGA is only for use in male patients.
- if you have severe liver disease.
- in combination with Ra-223 (used for the treatment of prostate cancer).
Do not take this medicine if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting treatment with this medicine:
- if you have liver problems
- if you have been told you have high blood pressure or heart failure or low potassium levels in your blood (low potassium levels in your blood can increase your risk of heart rhythm problems)
- if you have had other heart or blood vessel problems
- if you have a fast or irregular heart rhythm
- if you have difficulty breathing
- if you have gained weight quickly
- if you have swelling in your feet, ankles, or legs
- if you have taken ketoconazole in the past for prostate cancer
- about the need to take this medicine with prednisone or prednisolone
- about possible side effects on your bones
- if you have high blood sugar levels.
Tell your doctor if you have been told you have any heart or blood vessel disorder, including heart rhythm problems (arrhythmia), or if you are being treated with medicines for these disorders.
Tell your doctor if you have yellowing of the skin or eyes, dark urine, or severe nausea or vomiting, as these can be signs of liver problems. Rarely, acute liver failure (which can be life-threatening) may occur.
A decrease in red blood cell count, reduced sexual desire, and cases of muscle weakness and/or muscle pain may occur.
ZYTIGA must not be taken in combination with Ra-223 due to a possible increased risk of bone fractures or death.
If you plan to take Ra-223 after treatment with ZYTIGA and prednisone/prednisolone, you must wait 5 days before starting Ra-223 treatment.
If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
Blood tests
ZYTIGA may affect your liver even if you have no symptoms. While you are taking this medicine, your doctor will regularly perform blood tests to check for any effect on your liver.
Children and adolescents
This medicine must not be used in children or adolescents. If a child or adolescent accidentally takes ZYTIGA, they should go to the hospital immediately and take this leaflet with them to show to the emergency doctor.
Other medicines and ZYTIGA
Consult your doctor or pharmacist before taking any other medicine.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is important because ZYTIGA may increase the effects of certain medicines, including heart medicines, sedatives, some diabetes medicines, herbal medicines (e.g., St. John's Wort), and others. Your doctor may need to change the dose of these medicines. Also, some medicines may increase or decrease the effects of ZYTIGA. This may lead to side effects or ZYTIGA may not work as well as it should.
Androgen deprivation treatment may increase the risk of heart rhythm problems. Tell your doctor if you are being treated with medicines:
- used to treat heart rhythm problems (e.g., quinidine, procainamide, amiodarone, and sotalol);
- that increase the risk of heart rhythm problems [e.g., methadone (used for pain relief and as part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics (used for severe mental illnesses)].
Consult your doctor if you are taking any of the medicines listed above.
ZYTIGA with food
- This medicine must not be taken with food (see section 3, "How to take this medicine").
- Taking ZYTIGA with food may cause side effects.
Pregnancy and breastfeeding
ZYTIGA is not indicated in women.
- This medicine may harm the fetus if taken by a pregnant woman.
- Pregnant women or women who think they may be pregnant should wear gloves if they need to touch or handle ZYTIGA.
- If you have sex with a woman who can become pregnant, you must use a condom and another effective method of birth control.
- If you have sex with a pregnant woman, you must use a condom to protect the fetus.
Driving and using machines
It is unlikely that this medicine will affect your ability to drive or use tools or machines.
ZYTIGA contains lactose and sodium
- ZYTIGA contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
- This medicine contains 27.2 mg of sodium (a major component of cooking/table salt) in each dose of four tablets. This is equivalent to 1.36% of the maximum recommended daily intake of sodium for an adult.
3. How to take ZYTIGA
Always take this medicine exactly as your doctor has told you. If you are not sure, consult your doctor or pharmacist.
How much to take
The recommended dose is 1,000 mg (four tablets) once a day.
How to take this medicine
- Take this medicine by mouth.
- Do not take ZYTIGA with food.Taking ZYTIGA with food may cause more medicine to be absorbed by the body than necessary, which can cause side effects.
- Take the ZYTIGA tablets as a single dose once a day on an empty stomach. ZYTIGA should be taken at least 2 hours after eating and no food should be consumed for at least 1 hour after taking ZYTIGA (see section 2, "ZYTIGA with food").
- Swallow the tablets whole with water.
- Do not break the tablets.
- ZYTIGA is given together with a medicine called prednisone or prednisolone. Take prednisone or prednisolone exactly as your doctor has told you.
- You will need to take prednisone or prednisolone every day while you are taking ZYTIGA.
- If you have a medical emergency, it may be necessary to adjust the amount of prednisone or prednisolone you take. Your doctor will tell you if you need to change the dose of prednisone or prednisolone. Do not stop taking prednisone or prednisolone unless your doctor tells you to.
Your doctor may also prescribe other medicines while you are taking ZYTIGA and prednisone or prednisolone.
If you take more ZYTIGA than you should
If you take more than you should, consult your doctor or go to the hospital immediately.
If you forget to take ZYTIGA
- If you forget to take ZYTIGA or prednisone or prednisolone, take your normal dose the next day.
- If you forget to take ZYTIGA or prednisone or prednisolone for more than one day, consult your doctor immediately.
If you stop taking ZYTIGA
Do not stop taking ZYTIGA or prednisone or prednisolone unless your doctor tells you to.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking ZYTIGA and contact your doctor immediately if you experience any of the following:
- Muscle weakness, muscle contractions, or rapid heart rate (palpitations).
These may be signs of low potassium levels in your blood.
Other side effects are:
Very common(may affect more than 1 in 10 people):
Fluid retention in the legs or feet, low potassium levels in the blood, increased liver function tests, high blood pressure, urinary tract infection, diarrhea.
Common(may affect up to 1 in 10 people):
High levels of fats in the blood, chest pain, irregular heart rhythm (atrial fibrillation), heart failure, fast heart rate, severe infections called sepsis, bone fractures, indigestion, blood in the urine, skin rash.
Uncommon(may affect up to 1 in 100 people):
Problems with the adrenal glands (related to problems with salt and water), abnormal heart rhythm (arrhythmia), muscle weakness and/or muscle pain.
Rare(may affect up to 1 in 1,000 people):
Lung inflammation (also called allergic alveolitis).
Acute liver failure (also called acute hepatic failure).
Frequency not known(cannot be estimated from the available data):
Heart attack, changes in the electrocardiogram (ECG) (prolonged QT), and severe allergic reactions with difficulty swallowing or breathing, face, lips, tongue, or throat swelling, or itchy rash.
Bone density loss may occur in men receiving treatment for prostate cancer. ZYTIGA in combination with prednisone or prednisolone may increase this bone density loss.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of ZYTIGA
- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton and on the label of the bottle. The expiry date refers to the last day of that month.
- No special storage conditions are required.
- Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6. Contents of the pack and further information
Composition of ZYTIGA
- The active substance is abiraterone acetate. Each tablet contains 250 mg of abiraterone acetate.
- The other ingredients are microcrystalline cellulose, sodium croscarmellose, lactose monohydrate, magnesium stearate, povidone (K29/K32), anhydrous colloidal silica, and sodium lauryl sulfate (see section 2, "ZYTIGA contains lactose and sodium").
Appearance and packaging
- ZYTIGA tablets are white or almost white, oval (15.9 mm long x 9.5 mm wide), with "AA250" engraved on one side.
- The tablets are packaged in a plastic bottle with a child-resistant closure. Each bottle contains 120 tablets. Each carton contains one bottle.
Marketing authorisation holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Manufacturer
Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
I-04100 Latina, Italy
You can request more information about this medicine from the local representative of the marketing authorisation holder:
België/Belgique/Belgien Janssen-Cilag NV Tel/Tél: +32 14 64 94 11 | Lietuva UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 |
| Luxembourg/Luxemburg Janssen-Cilag NV Tel/Tél: +32 14 64 94 11 |
Ceská republika Janssen-Cilag s.r.o. Tel. +420 227 012 227 | Magyarország Janssen-Cilag Kft. Tel.: +36 1 884 2858 |
Danmark Janssen-Cilag A/S Tlf: +45 45 94 82 82 | Malta AM MANGION LTD. Tel: +356 2397 6000 |
Deutschland Janssen-Cilag GmbH Tel: +49 2137 955 955 | Nederland Janssen-Cilag B.V. Tel: +31 76 711 1111 |
Eesti UAB "JOHNSON & JOHNSON" Eesti filiaal Tel: +372 617 7410 | Norge Janssen-Cilag AS Tlf: +47 24 12 65 00 |
Ελλάδα Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε. Τηλ: +30 210 80 90 000 | Österreich Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 |
España Janssen-Cilag, S.A. Tel: +34 91 722 81 00 | Polska Janssen-Cilag Polska Sp. z o.o. Tel.+48 22 237 60 00 |
France Janssen-Cilag Tél: 0 800 25 50 75 / +33 1 55 00 40 03 | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 |
Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 | România Johnson & Johnson România SRL Tel: +40 21 207 1800 |
Ireland Janssen Sciences Ireland UC Tel: +353 1 800 709 122 | Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 |
Ísland Janssen-Cilag AB c/o Vistor hf. Sími: +354 535 7000 | Slovenská republika Johnson & Johnson, s.r.o. Tel: +421 232 408 400 |
Italia Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 | Suomi/Finland Janssen-Cilag Oy Puh/Tel: +358 207 531 300 |
Κύπρος Βαρνάβας Χατζηπαναγής Λτδ Τηλ: +357 22 207 700 | Sverige Janssen-Cilag AB Tfn: +46 8 626 50 00 |
Latvija UAB "JOHNSON & JOHNSON" filiale Latvija Tel: +371 678 93561 | United Kingdom (Northern Ireland) Janssen Sciences Ireland UC Tel: +44 1 494 567 444 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/, and on the Spanish Agency for Medicines and Health Products (AEMPS) web site (http://www.aemps.gob.es/).
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to ZYTIGA 250 mg TABLETSDosage form: TABLET, 250 mgActive substance: abirateroneManufacturer: Accord Healthcare S.L.U.Prescription requiredDosage form: TABLET, 500 mgActive substance: abirateroneManufacturer: Accord Healthcare S.L.U.Prescription requiredDosage form: TABLET, 500 mgActive substance: abirateroneManufacturer: Cipla EuropePrescription required
Online doctors for ZYTIGA 250 mg TABLETS
Discuss questions about ZYTIGA 250 mg TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
